Consensus is for FY25 revenue $1.37B. Maintains guidance for U.S. Thrombectomy growth of 20% to 21% compared to 2024 levels and for both gross margin and operating margin for FY25.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PEN:
- Buy Rating on Penumbra: Capitalizing on Positive STORM-PE Trial Results and Market Misunderstanding
- Penumbra Inc. (PEN) Q3 Earnings Cheat Sheet
- William Blair healthcare analysts hold analyst/industry conference call
- Penumbra Inc. Launches i-RISE Study to Enhance Stroke Treatment Insights
- Penumbra Inc.’s STRIKE-PE Study: A Game Changer for Pulmonary Embolism Treatment?